Impact of Immune-Related Adverse Events on Advanced Gastric Cancer Outcomes
Author Information
Author(s): Zhang Tianhang, Lv Haitao, Li Jiasong, Zhang Shasha, Zhang Jingjing, Wang Siqi, Wang Yingnan, Guo Zhanjun
Primary Institution: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Hypothesis
The occurrence of immune-related adverse events (irAEs) is associated with better outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Conclusion
Multi-organ irAEs and certain organ-specific irAEs can serve as predictive indicators for the efficacy of immune checkpoint inhibitor treatment in advanced gastric cancer patients.
Supporting Evidence
- Patients with irAEs had a higher disease control rate (DCR) of 78.8% compared to 67.4% in non-irAE patients.
- Multi-irAEs were identified as an independent risk factor for improved progression-free survival (PFS) and overall survival (OS).
- The thyroid, adrenal gland, and skin irAEs were associated with better survival outcomes.
Takeaway
If patients with advanced gastric cancer have side effects from their treatment, it might actually mean the treatment is working better for them.
Methodology
The study evaluated 288 patients with advanced gastric cancer, assessing the impact of uni-irAE and multi-irAEs on survival using Kaplan–Meier and Cox regression analyses.
Potential Biases
Potential biases include differences in treatment protocols and lack of diversity in the patient population.
Limitations
The study is retrospective, conducted at a single center with a relatively small sample size, and may have selection biases.
Participant Demographics
Patients included both genders, aged over 28, with advanced unresectable adenocarcinoma gastric cancer.
Statistical Information
P-Value
p=0.031 for PFS, p=0.002 for OS
Confidence Interval
95% CI 0.41~0.96 for PFS, 95% CI 0.29~0.76 for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website